David Alain Wohl, M.D., is a professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC). He is site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AIDS Education and Training Center (AETC), and co-director of HIV services for the North Carolina state prison system. In 2014, he became co-director of the UNC-Duke Clinical RM Ebola Response Consortium.
Dr. Wohl's research aims to optimize the treatment of HIV, including identifying the most effective therapeutic approaches and minimizing the adverse effects of therapy. He is also active in investigations focused on populations vulnerable to HIV, such as the incarcerated. He is active within the U.S. AIDS Clinical Trials Group and HIV Prevention Trials Network and served two terms as a member of the U.S. Department of Health and Human Services Antiretroviral Guidelines Panel.
As part of the response to the 2013-2016 Ebola outbreak in West Africa, Dr. Wohl led UNC clinical research efforts to test interventions for Ebola Virus Disease in Liberia and now directs a clinical cohort of Ebola survivors.
In addition to his research and administrative activities, Dr. Wohl maintains a large HIV continuity clinic at UNC.
Dr. Wohl has attended advisory boards for Abbott Laboratories, Tibotec, Janssen Pharmaceuticals, ViiV Healthcare, and Gilead Sciences. In addition, his university has received support for his research from Gilead Sciences and ViiV Healthcare. These disclosures were last updated on November 17, 2017.
|Gene Therapy in HIV Cure Research|
|Bias Is Everywhere: Uncovering HIV Prejudice to Improve Service Delivery|
|One Doc's Advice for Caring for Elderly Patients With HIV|
|Making HIV -- and Bias -- 'Part of the Party' to Strengthen Our Response to the Epidemic|
|Who Tends to Gain Weight With HIV Treatment?|